21:40:37 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-10-09 Årsstämma
2025-09-11 Bokslutskommuniké 2025
2025-02-05 Kvartalsrapport 2025-Q2
2024-10-11 X-dag ordinarie utdelning CHEMM 0.00 DKK
2024-10-10 Årsstämma
2024-09-11 Bokslutskommuniké 2024
2024-02-05 Kvartalsrapport 2024-Q2
2023-10-13 X-dag ordinarie utdelning CHEMM 6.00 DKK
2023-10-12 Årsstämma
2023-09-14 Bokslutskommuniké 2023
2023-05-09 15-10 2023-Q3
2023-02-09 Kvartalsrapport 2023-Q2
2022-10-14 X-dag ordinarie utdelning CHEMM 0.00 DKK
2022-10-13 Årsstämma
2022-09-15 Bokslutskommuniké 2022
2022-02-08 Kvartalsrapport 2022-Q2
2021-10-15 X-dag ordinarie utdelning CHEMM 4.00 DKK
2021-10-14 Årsstämma
2021-09-16 Bokslutskommuniké 2021
2021-02-05 Kvartalsrapport 2021-Q2
2020-10-09 X-dag ordinarie utdelning CHEMM 1.50 DKK
2020-10-08 Årsstämma
2020-09-17 Bokslutskommuniké 2020
2020-02-07 Kvartalsrapport 2020-Q2
2020-01-14 X-dag bonusutdelning CHEMM 13
2020-01-13 Extra Bolagsstämma 2020
2019-10-11 X-dag ordinarie utdelning CHEMM 7.50 DKK
2019-10-10 Årsstämma
2019-09-17 Bokslutskommuniké 2019
2019-02-08 Kvartalsrapport 2019-Q2
2018-10-12 X-dag ordinarie utdelning CHEMM 0.00 DKK
2018-10-11 Årsstämma
2018-09-18 Bokslutskommuniké 2018
2018-02-09 Kvartalsrapport 2018-Q2
2017-11-15 Årsstämma
2017-10-13 X-dag ordinarie utdelning CHEMM 0.00 DKK
2017-10-12 Årsstämma
2017-09-19 Bokslutskommuniké 2017
2017-02-10 Kvartalsrapport 2017-Q2
2016-10-14 X-dag ordinarie utdelning CHEMM 0.00 DKK
2016-10-13 Årsstämma
2016-09-20 Bokslutskommuniké 2016
2016-02-26 Kvartalsrapport 2016-Q2
2015-10-09 X-dag ordinarie utdelning CHEMM 0.00 DKK
2015-10-08 Årsstämma
2015-05-15 Kvartalsrapport 2015-Q3
2014-10-10 X-dag ordinarie utdelning CHEMM 0.00 DKK
2014-10-09 Årsstämma
2014-05-15 Kvartalsrapport 2014-Q3
2013-11-15 Kvartalsrapport 2014-Q1
2013-10-11 X-dag ordinarie utdelning CHEMM 0.00 DKK
2013-10-10 Årsstämma
2013-07-25 Extra Bolagsstämma 2013
2013-05-14 Kvartalsrapport 2013-Q3
2012-11-14 Kvartalsrapport 2013-Q1
2012-10-12 X-dag ordinarie utdelning CHEMM 0.00 DKK
2012-10-11 Årsstämma
2012-05-11 Kvartalsrapport 2012-Q3
2011-11-11 Kvartalsrapport 2012-Q1
2011-10-14 X-dag ordinarie utdelning CHEMM 0.00 DKK
2011-10-13 Årsstämma
2011-05-13 Kvartalsrapport 2011-Q3
2010-11-12 Kvartalsrapport 2011-Q1
2010-10-06 X-dag ordinarie utdelning CHEMM 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
ChemoMetec är verksamt inom medicinteknik. Bolaget är specialiserat inom design, utveckling och produktion av patenterade instrument för cellräkning och cellanalys. Bolaget samarbetar och stadgar avtal med aktörer som forskningsinstitut, universitet, livsmedelsbolag, sjukhus och specialkliniker. Kunderna återfinns på en global marknad. Bolaget grundades ursprungligen 1997 och har sitt huvudkontor i Alleröd, Danmark.
2022-09-15 08:30:00

ANNOUNCEMENT NO. 229

15 September 2022


Annual Report 2021/22 (1 July 2021 - 30 June 2022)


Strong growth despite challenging conditions

ChemoMetec grew its revenue by 52% in 2021/22 from DKK 281.1 million to DKK 427.2 million despite the extraordinary market conditions caused by Covid-19 and the war in Ukraine, including supply chain shortages. As a result, EBITDA grew from DKK 135.6 million to DKK 222.9 million, a 64% increase. As in previous years, growth was primarily driven by increasing sales within cell-based therapy, particularly in the North American market.

“In the past year, we have focused intently on coping with various challenges in the wake of Covid-19 and the war in Ukraine – and more generally on navigating ChemoMetec safely through a period in which high growth places great demands on the entire company. These efforts were generally successful, and we are very pleased that our organisation was able to generate this level of growth under difficult circumstances. Going into the new financial year, we have a period ahead of us that will be marked by continuing uncertainty, but we are generally in a good position. We will therefore continue to invest in a sustainable foundation for our business. At the same time, we look forward to launching our new XcytoMatic cell counters, which are expected to contribute significantly to driving the continued growth in the years ahead,” says Steen Søndergaard, CEO.


Financial results

  • ChemoMetec grew its revenue by 52% in the financial year 2021/22, and total revenue amounted to DKK 427.2 million (2020/21: DKK 281.1 million). Revenue growth was driven by increased sales of instruments, consumables, and services in all key geographies.
  • Sales of analytical instruments were up by 57% to DKK 214.9 million, corresponding to 50% of total revenue.
  • Sales of consumables, comprising cassettes, slides, reagents, test kits, etc., grew by 31% to DKK 147.0 million, corresponding to 34% of revenue.
  • Sales of the services, comprising service contracts, installations, and various consulting services, were up by 111% in 2021/22 to DKK 59.9 million, corresponding to 14% of revenue.
  • Sales of our latest cell counter, the NC-202, maintained momentum, growing by 128% in the past year.
  • EBITDA was DKK 222.9 million, an increase of DKK 87.3 million relative to 2020/21, and the EBITDA margin was 52%, against 48% the previous year.
  • Profit for the year was DKK 159.5 million, which was DKK 71.1 million more than the previous year (2020/21: DKK 88.4 million).
  • Annual revenue and EBITDA are in line with the most recent guidance announced on 15 August 2022 but are significantly higher than the guidance presented in the 2020/21 annual report.
  • The Board of Directors proposes to the general meeting that no dividend be distributed for the 2021/22 financial year. This is based, among other things, on ChemoMetec’s plans to invest in expanding its production and warehouse facilities to support the company’s continued growth.


Guidance

  • For 2022/23, ChemoMetec expects revenue in the range of DKK 485-505 million and EBITDA in the range of DKK 245-260 million.
  • Investment in e.g. product development, production facilities, and intangible assets is expected to amount to approximately DKK 70 million.


Attached to this announcement

  • The Annual Report 2021/22 (Danish)
  • Extract from annual report 2021/22 (English)

The annual report and the extract may also be downloaded from ChemoMetec’s website www.chemometec.com



More information

Steen Søndergaard, CEO, ChemoMetec A/S
Telephone (+45) 48 13 10 20        



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to www.chemometec.com.